ALS Association Statement on Positive Phase 3 Results for Ulefnersen in FUS-ALS
Phase 3positiveulefnersenQalsodyPositive
AI Analysis
Summary
Ulefnersen, an investigational antisense therapy for FUS-ALS, met its primary endpoint in the Phase 3 FUSION trial. This represents the second antisense therapy approved or showing positive results for this rare ALS subtype.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met primary endpoint in Phase 3 FUSION trial
Importance:8/10
Sentiment:
0.85
antisense therapyFUS-ALSPhase 3 resultsFUSION trialrare disease
Read the original article
Published by PR Newswire Biotech on September 22, 2026 3:55 PM